Second-line randomized trials in epithelial ovarian cancer

International Journal of Gynecological Cancer

Volumn 18, Issue SUPPL. 1, 2008, Pages 59-66

  Vermorken, J B ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Randomized trials; Recurrent ovarian cancer

Indexed keywords

ALTRETAMINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; LEUPRORELIN; MELPHALAN; NAVELBINE; OXALIPLATIN; PACLITAXEL; TOPOTECAN; TREOSULFAN;

ALOPECIA; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HAND FOOT SYNDROME; HUMAN; LEUKEMIA; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PARESTHESIA; PRIORITY JOURNAL; QUALITY OF LIFE; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 40849139532     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.01161.x     Document Type: Article

References (48)

1. Thigpen T, Stuart G, du Bois A et al. Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens. Ann Oncol 2005 16 : 13 9.
2. Piccart MJ, Bertelsen K, Stuart G et al. Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer 2003 13 : 144 8.
3. Hamilton TC, Berek JS, Kaye SB. Basic research: how much do we know, and what are we likely to learn about ovarian cancer in the near future? Ann Oncol 1999 10 : S69 73.
4. Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 2002 7 : 20 8.
5. Gore ME, Fryatt I, Wiltshaw E et al. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 1990 36 : 207 11.
6. Markman M, Rothmans R, Hakes T et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991 9 : 389 93.
7. Sabbatini P, Spriggs D. Salvage therapy for ovarian cancer. Oncology 1998 12 : 833 48.
8. Eisenhauer EA, Vermorken JB, Van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: an analysis of 704 patients. Ann Oncol 1997 8 : 963 8.
9. Eisenhauer EA, Gore M, Neijt JP. Ovarian cancer: should we be managing patients with good and bad prognostic factors in the same manner? Ann Oncol 1999 10 (Suppl 1 S9 S15.
10. Ozols RF, Schwartz PE, Eifel PJ. Treatment of advanced-stage ovarian cancer. In : DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. Philadelphia, PA : Lippincott-Raven, 1997 : 1514 39.
11. Markman M. Single-agent carboplatin is the treatment of choice in recurrent, potentially platinum-sensitive epithelial ovarian cancer. In : Perry MC, ed. ASCO educational book. Baltimore : Lippincott Williams & Wilkins, 2002 : 512 23.
12. Vermorken JB, Parmar MKB, Brady MF et al. Clinical trials in ovarian carcinoma: study methodology. Ann Oncol 2005 16 : viii20 29.
13. Lakusta CM, Atkinson MJ, Robinson JW et al. Quality of life in ovarian cancer patients receiving chemotherapy. Gynecol Oncol 2001 81 : 490 5.
14. du Bois A, Luck HJ, Meier W et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003 95 : 1320 9.
15. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994 12 : 2654 66.
16. Omura GA, Brady MF, Look KY et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. J Clin Oncol 2003 21 : 2843 8.
17. Rosenberg P, Andersson H, Boman K et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncol 2002 41 : 418 24.
18. Gore M, Oza A, Rustin G et al. A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. Eur J Cancer 2002 38 : 57 63.
19. Hoskins P, Eisenhauer E, Beare S et al. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 1998 16 : 2233 7.
20. Kuhn W, Schmalfeldt B, Pache L et al. Disease-adapted relapse therapy for ovarian cancer: results of a prospective study. Int J Oncol 1998 13 : 57 63.
21. Harries M, Gore M. Part II: chemotherapy for epithelial ovarian cancer - treatment of recurrent disease. Lancet Oncol 2002 3 : 537 45.
22. Sessa C, Marsoni S. Randomized single-agent trials in recurrent epithelial ovarian cancer. Int J Gynecol Cancer 2005 15 : 247 51.
23. Smith JP, Rutledge FN. Random study of hexamethylmelamine, 5-fluorouracil and melphalan in treatment of advanced carcinoma of the ovary. Natl Cancer Inst Monogr 1975 42 : 169 72.
24. De Palo GM, De Lena M, Di Re F et al. Melphalan versus adriamycin in the treatment of advanced ovarian carcinoma. Cancer Treat Rep 1975 141 : 899 902.
25. ten Bokkel Huinink W, Gore M, Carmichael J et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997 15 : 2183 93.
26. Piccart MJ, Green JA, Lacave AJ et al. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. J Clin Oncol 2000 18 : 1193 202.
27. O'Byrne KJ, Bliss P, Graham JD et al. A phase III study of doxil/caelyx versus paclitaxel in platinum-treated taxane-naive relapsed ovarian cancer [abstract]. Proc Am Soc Clin Oncol 2002 21 : 203a. Abstract 808.
28. du Bois A, Meier W, Lück HJ et al. Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer. Ann Oncol 2002 13 : 251 7.
29. Vermorken J, Gore M, Perren T et al. Multicenter randomized phase II study of oxaliplatin or topotecan in platinum-pretreated epithelial ovarian cancer patients [abstract]. Proc Am Soc Clin Oncol 2001 20 : 212a. Abstract 847.
30. Meier W, du Bois A, Reuss A et al. Topotecan vs treosulfan in early recurrent ovarian cancer after primary platinum/paclitaxel chemotherapy. A prospective randomized phase III trial of the AGO Ovarian Cancer Study Group [abstract]. Int J Gynecol Cancer 2004 14 : 2. Abstract 005.
31. Gordon A, Fleagle JT, Guthrie D et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001 19 : 3312 22.
32. Ferrandina G, Lorusso D, Pignata S et al. A randomized phase III study of gemcitabine versus pegylated liposomal doxorubicin in progressive/recurrent ovarian cancer [abstract]. J Clin Oncol 2007 25 : 275s. Abstract 5506.
33. Gordon AN, Tonda M, Sun S et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004 95 : 1 8.
34. ten Bokkel Huinink W, Lane SR, Ross GA. Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann Oncol 2004 15 : 100 3.
35. Pater JL, Carmichael JA, Krepart GV et al. Second-line chemotherapy of stage III-IV ovarian carcinoma: a randomized comparison of melphalan to melphalan and hexamethylmelamine in patients with persistent disease after doxorubicin and cisplatin. Cancer Treat Rep 1987 71 : 277 81.
36. Park RC, Blom J, Disaia PJ, Lagasse LD, Blessing JA. Treatment of women with disseminated or recurrent advanced ovarian cancer with melphalan alone, in combination with 5-fluorouracil and dactinomycin or with the combination of cytoxan, 5-fluorouracil and dactinomycin. Cancer 1980 45 : 2529 42.
37. Cantu MG, Buda A, Parma G et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol 2002 20 : 1232 7.
38. Torri V, Floriani I, Tinazzi A et al. Randomized trial comparing paclitaxel + doxorubicin versus paclitaxel as second line therapy for advanced ovarian cancer patients in early progression after platinum-based chemotherapy [abstract]. Proc Am Soc Clin Oncol 2000 19 : 381a. Abstract 1506.
39. Bolis G, Parazzini F, Scarfone G et al. Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and -resistant ovarian cancer. Gynecol Oncol 1999 72 : 60 4.
40. Buda A, Floriani I, Rossi R et al. Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian collaborative study from the Mario Negri Institute, Milan, G.O.N.O. (Gruppo Oncologico Nord Ovest) group and I.O.R. (Istituto Oncologico Romagnolo) group. Br J Cancer 2004 90 : 2112 7.
41. Sehouli J, Sommer H, Klare P et al. A randomized multicenter phase III trial of topotecan monotherapy versus topotecan + etoposide versus topotecan + gemcitabine for second-line treatment of recurrent ovarian cancer [abstract]. J Clin Oncol 2006 24 : 263s. Abstract 5030.
42. Krafft W. The effectiveness of platinum in mono- and combination therapy in a prospective multicenter study. Zentralbl Gynakol 1989 111 : 938 46.
43. Bolis G, Scarfone G, Giardina G et al. Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer. Gynecol Oncol 2001 81 : 3 9.
44. Parmar MK, Ledermann JA, Colombo N et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer. The ICON4/AGO-OVAR-2.2 trial. Lancet 2003 361 : 2099 106.
45. Gonzales-Martin AJ, Calvo E, Bover I et al. Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Gruppo Español de Investigacion en Cancer de Ovario) study. Ann Oncol 2005 16 : 749 55.
46. Pfisterer J, Plante M, Vergote I et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006 24 : 4699 707.
47. Gonzalez-Martin A. Treatment of recurrent disease: randomized trials of monotherapy versus combination chemotherapy. Int J Gynecol Cancer 2005 15 : 241 6.
48. Orlando M, Costanzo MV, Chacon RD, Tajer CD. Randomized trials of combination chemotherapy versus monotherapy in relapsed ovarian carcinoma: a mea-analysis of published data [abstract]. J Clin Oncol 2007 25 : 280s. Abstract 5524.